DCTH Stock Overview
An interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Delcath Systems, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$17.10 |
| 52 Week High | US$17.15 |
| 52 Week Low | US$6.33 |
| Beta | 0.72 |
| 1 Month Change | 48.05% |
| 3 Month Change | 5.04% |
| 1 Year Change | 125.89% |
| 3 Year Change | 279.16% |
| 5 Year Change | 124.41% |
| Change since IPO | -100.00% |
Recent News & Updates
Delcath Systems, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
May 11
HEPZATO Launch And European Expansion Will Expand Treatment Access
May 02 Expansion in U.S. treatment centers and commercial teams is expected to drive significant revenue growth and improve operational efficiencies.Recent updates
Delcath Systems, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
May 11HEPZATO Launch And European Expansion Will Expand Treatment Access
May 02 Expansion in U.S. treatment centers and commercial teams is expected to drive significant revenue growth and improve operational efficiencies.With A 27% Price Drop For Delcath Systems, Inc. (NASDAQ:DCTH) You'll Still Get What You Pay For
Mar 11Delcath Systems, Inc.'s (NASDAQ:DCTH) P/S Is Still On The Mark Following 31% Share Price Bounce
Jan 18Does Delcath Systems (NASDAQ:DCTH) Have A Healthy Balance Sheet?
Dec 19Delcath Systems: Q3 Earnings Reveal HEPZATO KIT And CHEMOSAT Growth
Nov 18Delcath Systems, Inc.'s (NASDAQ:DCTH) P/S Is Still On The Mark Following 26% Share Price Bounce
Nov 01Delcath Systems, Inc.'s (NASDAQ:DCTH) 26% Jump Shows Its Popularity With Investors
Sep 10Is Delcath Systems (NASDAQ:DCTH) A Risky Investment?
Aug 27Delcath Systems, Inc. (NASDAQ:DCTH) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Aug 07Is Delcath Systems (NASDAQ:DCTH) Using Debt In A Risky Way?
Jan 15Delcath Systems (NASDAQ:DCTH) Has Debt But No Earnings; Should You Worry?
Oct 04Delcath Systems Q2 2022 Earnings Preview
Aug 05Shareholder Returns
| DCTH | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 15.2% | 3.4% | 5.3% |
| 1Y | 125.9% | 9.5% | 11.9% |
Return vs Industry: DCTH exceeded the US Medical Equipment industry which returned 8.3% over the past year.
Return vs Market: DCTH exceeded the US Market which returned 11.2% over the past year.
Price Volatility
| DCTH volatility | |
|---|---|
| DCTH Average Weekly Movement | 11.0% |
| Medical Equipment Industry Average Movement | 9.6% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: DCTH has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: DCTH's weekly volatility (11%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 96 | Gerard Michel | www.delcath.com |
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma.
Delcath Systems, Inc. Fundamentals Summary
| DCTH fundamental statistics | |
|---|---|
| Market cap | US$558.96m |
| Earnings (TTM) | -US$14.21m |
| Revenue (TTM) | US$53.85m |
11.1x
P/S Ratio-41.9x
P/E RatioIs DCTH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DCTH income statement (TTM) | |
|---|---|
| Revenue | US$53.85m |
| Cost of Revenue | US$8.13m |
| Gross Profit | US$45.72m |
| Other Expenses | US$59.93m |
| Earnings | -US$14.21m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.41 |
| Gross Margin | 84.90% |
| Net Profit Margin | -26.38% |
| Debt/Equity Ratio | 0% |
How did DCTH perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/16 22:30 |
| End of Day Share Price | 2025/05/16 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Delcath Systems, Inc. is covered by 12 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Gorman | BTIG |
| Marie Thibault | BTIG |
| John Newman | Canaccord Genuity |